NEWS

January 13, 2020

WALTHAM Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced the closing of its previously announced underwritten public offering of...

January 8, 2020

Oxford and Manchester, UK – Cytox, which provides non-invasive, risk assessment and patient stratification tools for Alzheimer's disease and dementia, has appointed Dr Ian Gilham as the new Chairman of the Board. Dr Gilham, who brings significant exp...

January 7, 2020

Pegcetacoplan met the primary endpoint in the PEGASUS study, demonstrating superiority to eculizumab (p<0.0001) with an improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16

Safety profile of pegcetacoplan was comparable to eculizumab in...

November 21, 2019

Clinical and commercial agreement using MaxCyte’s recently launched ExPERT™ platform enables up to five of Vor’s engineered cell therapies and includes development and approval milestones and sales-based payments 

Takes MaxCyte’s total number of partn...

October 25, 2019

MCY-M11 is being evaluated in relapsed/refractory ovarian cancer and peritoneal mesothelioma

CARMA platform offers faster manufacturing speeds, broader therapeutic applications, combination opportunities and repeat dosing potential

Gaithersburg, Maryla...

October 8, 2019

Gaithersburg, Maryland – October 7, 2019: Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and MaxCyte, Inc., the global cell-based therapies and life sciences company, today announced a new clinical and commercial license agre...

September 19, 2019

​CRESTWOOD, Ky. and WALTHAM, Mass., - Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, t...

September 4, 2019

​CRESTWOOD, Ky. and WALTHAM, Mass., - Apellis Pharmaceuticals Inc., (Nasdaq:APLS) announced today the dosing of the first patient in the Phase 3 clinical study PRINCE (APL2-308), evaluating the efficacy and safety of APL-2 for treatment-naïve patient...

July 23, 2019

​CRESTWOOD, Ky. and WALTHAM, Mass., - Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, a...

July 19, 2019

​CRESTWOOD, Ky. and WALTHAM, Mass., - Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the control of the complement system, toda...

Please reload

Featured Posts
Please reload

See News By Company
See News By Month
Please reload

7910 Woodmont Avenue,Suite 1210
Bethesda, Maryland 20814, U.S.A. 
info@mlsvfund.com |   +1 301 298 5455

© 2018  by MASA Life Science Ventures, LP